Prosperitas Financial LLC Buys 88,922 Shares of Hims & Hers Health, Inc. $HIMS

Prosperitas Financial LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, HoldingsChannel.com reports. The firm bought 88,922 shares of the company’s stock, valued at approximately $2,649,000.

Several other hedge funds and other institutional investors also recently modified their holdings of HIMS. VestGen Advisors LLC lifted its position in shares of Hims & Hers Health by 256.4% during the 3rd quarter. VestGen Advisors LLC now owns 20,578 shares of the company’s stock worth $613,000 after buying an additional 14,804 shares during the last quarter. Evergreen Capital Management LLC bought a new position in shares of Hims & Hers Health in the third quarter worth about $446,000. Sterling Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 839.5% in the third quarter. Sterling Capital Management LLC now owns 7,131 shares of the company’s stock worth $212,000 after acquiring an additional 6,372 shares during the last quarter. Lake Street Private Wealth LLC boosted its stake in shares of Hims & Hers Health by 1.0% in the 3rd quarter. Lake Street Private Wealth LLC now owns 179,206 shares of the company’s stock valued at $5,339,000 after purchasing an additional 1,858 shares in the last quarter. Finally, USAdvisors Wealth Management LLC grew its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. USAdvisors Wealth Management LLC now owns 8,500 shares of the company’s stock valued at $253,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 7.0%

NYSE:HIMS opened at $27.59 on Friday. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $48.34. The firm’s fifty day moving average is $29.04 and its 200-day moving average is $27.08. The firm has a market cap of $6.44 billion, a P/E ratio of -43.79 and a beta of 2.44. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same period last year, the company posted $0.17 EPS. The business’s revenue was up 38.2% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current year.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: U.S. Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The policy could improve Hims & Hers’ access to compounded treatments and support growth, although its temporary nature creates continuing uncertainty. Hims & Hers Jumped as HHS Uses Enforcement Discretion to Open Peptide Compounding
• Positive Sentiment: Earlier strength in telehealth stocks following Teladoc’s better-than-expected results provided some support for Hims & Hers and highlighted continued investor interest in digital-health companies. Teladoc Soars as Revenue and Profit Beat Estimates
• Neutral Sentiment: Insider Soleil Boughton sold 3,462 shares for approximately $95,551 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s position by about 1.16% and is therefore a limited signal about management’s outlook. SEC Insider Trading Filing
• Negative Sentiment: Multiple law firms are soliciting investors ahead of the November 2, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases from August 4, 2025, through July 29, 2026. The litigation stems in part from allegations associated with an FTC complaint and could expose Hims & Hers to legal expenses, potential damages, reputational harm and further scrutiny. The repeated notices appear to be the primary near-term catalyst weighing on the stock. HIMS Securities Class Action Deadline Alert

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 3,462 shares of Hims & Hers Health stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the completion of the sale, the insider owned 293,886 shares in the company, valued at $8,111,253.60. The trade was a 1.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $29.70, for a total transaction of $59,400.00. Following the transaction, the chief financial officer owned 234,527 shares in the company, valued at $6,965,451.90. The trade was a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock valued at $3,826,977 in the last quarter. 11.76% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of research analyst reports. TD Cowen raised their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a report on Friday, September 11th. They set a “neutral” rating and a $32.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Bank of America increased their target price on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Finally, Citigroup cut their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.